New York, New York, United States Related Funds
| Fund Name | Location |
| Blue Dynamic | - |
| Cellebrite | HaMerkaz, Israel, Petah Tiqva |
| GLOBAL AGRINNO | Hungary, Vas, Vasvár |
| H&M CO:LAB | Stockholm, Stockholm County, Sweden |
| Hawkshead Capital | - |
| Shanda Holdings | - |
| SK Materials | Seoul, Seoul-t'ukpyolsi, South Korea |
| Tennessee Community Ventures | Nashville, Tennessee, United States |
| Value Invest Korea (VIK) | Seoul, Seoul-t'ukpyolsi, South Korea |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Evergreen Theragnostics | $26M | 16 Apr 2024 | Jersey City, New Jersey, United States | ||
Ascend | $65M | 09 May 2023 | - | ||
Tourmaline Bio | 01 May 2022 | New York, New York, United States | |||
Persivia | $15M | 10 Oct 2019 | Marlborough, Massachusetts, United States | ||
CorneaGen | $37M | 10 Jul 2019 | Seattle, Washington, United States |
– Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing.
– The round was led by Petrichor Healthcare Capital Management with participation from existing shareholders.
– Proceeds will be used to accelerate Leukocare’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation, as well as the emerging field of mRNA formulation, and to expand its suite of bioinformatics capabilities.
– ITM announced the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors.
– The proceeds will support the expansion of ITM’s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a. 177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
– Further details of the financing were not disclosed.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Evergreen Theragnostics | $26M | 16 Apr 2024 | Jersey City, New Jersey, United States | ||
Ascend | $65M | 09 May 2023 | - | ||
Tourmaline Bio | 01 May 2022 | New York, New York, United States | |||
Persivia | $15M | 10 Oct 2019 | Marlborough, Massachusetts, United States | ||
CorneaGen | $37M | 10 Jul 2019 | Seattle, Washington, United States |
